SureNano's GEP-44: Next-Gen GLP-1 Therapy Targets Obesity
May 12, 2026 — SureNano Science (OTCQB: SURNF) featured in BioMedWire editorial for GEP-44 triple agonist peptide, a next-gen GLP-1 therapy targeting obesity and metabolic diseases with improved tolerability and potential non-injectable delivery.